CHEMOTHERAPY FOR METASTATIC NON-SMALL CELL BRONCHOGENIC-CARCINOMA - CYCLOPHOSPHAMIDE, DOXORUBICIN, AND ETOPOSIDE VERSUS MITOMYCIN AND VINBLASTINE (EST-2575, GENERATION-IV)

Google Scholar
  • 1 January 1984
    • journal article
    • research article
    • Vol. 68  (11) , 1325-1329
Abstract
Between March-Dec. 1979, the Eastern Cooperative Oncology Group [USA] (ECOG) compared the CAVP16 (cyclophosphamide, doxorubicin, etoposide) and MV (mitomycin and vinblastine) regimens in 200 patients with metastatic non-small cell bronchogenic carcinoma. Most patients were ambulatory (ECOG performance status 0, 1; 75%) and had not received prior radiation therapy (76%). The CAVP16 regimen resulted in 1 complete and 13 partial responses (14%); the MV regimen resulted in 2 complete and 11 partial responses (13%). These results did not differ significantly (P = 0.45), nor did the results for median survival (18 wk for each regimen). Good performance status and prior surgical resection were positive predictors of improved survival. Toxicity was significant with 8 drug-related deaths, 6 due to leukopenia and infection and 1 each due to renal failure and interstitial pneumonitis. CAVP16 resulted in significantly more serious and life-threatening toxicity (P < 0.0001). Neither regimen is recommended for further study.